Published on
January 28, 2026
- 15:07 GMT
Highlight Therapeutics announces completion of enrollment for Ph 2b study of BO-112 in large, underserved BCC population
Highlight Therapeutics announces completion of enrollment for Phase 2b study of BO-112 in large, underserved basal cell carcinoma population VALèNCIA, VALENCIA, SPAIN, January 28, 2026 /EINPresswire.com/ -- Highlight Therapeutics (“Highlight”), a …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
